• Guardant Health disclosed published results from a prospective, multicenter COSMOS study evaluating its Reveal blood test in resected stage II-III melanoma.
• The paper has already been published in Cancer Research Communications.
• Findings supported the test’s ability to flag patients at higher recurrence risk and to detect relapse earlier than standard clinical identification.
• Results also indicated strong accuracy in patients who remained recurrence-free, supporting potential use in post-surgery surveillance decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051127BIZWIRE_USPR_____20261002_BW257126) on October 05, 2026, and is solely responsible for the information contained therein.